Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 May;19(3):305-9.
doi: 10.1097/MCP.0b013e32835f1b49.

Biomarkers in sepsis

Mervyn Singer  1
Affiliations
Free PMC article
Review

Biomarkers in sepsis

Mervyn Singer. Curr Opin Pulm Med. 2013 May.
Free PMC article

Abstract

Purpose of review: This review discusses the current developments in biomarkers for sepsis.

Recent findings: With quantum leaps in technology, an array of biomarkers will become available within the next decade as point-of-care tools that will likely revolutionize the management of sepsis. These markers will facilitate early and accurate diagnosis, faster recognition of impending organ dysfunction, optimal selection and titration of appropriate therapies, and more reliable prognostication of risk and outcome. These diagnostics will also enable an improved characterization of the biological phenotype underlying sepsis and thus a better appreciation of the condition.

Summary: The potential for novel biomarkers in sepsis will need to be properly realized with considerable funding, academic-industry collaborations, appropriate investigations and validation in heterogenous populations, but these developments do hold the capacity to transform patient care and outcomes.

PubMed Disclaimer

Figures

Box 1
Box 1
no caption available
See this image and copyright information in PMC

References

    1. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055–2064. - PubMed

    2. This trial resulted in the withdrawal of the only licensed drug for sepsis immunomodulation.

    1. Nature Medicine News Biologic drugs set to top 2012 sales. Nat Med 2012; 18:636. - PubMed
    1. Angus DC. The search for effective therapy for sepsis: back to the drawing board? JAMA 2011; 306:2614–2615. - PubMed
    1. Venet F, Davin F, Guignant C, et al. Early assessment of leukocyte alterations at diagnosis of septic shock. Shock 2010; 34:358–363. - PubMed
    1. Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009; 180:640–648. - PubMed

Publication types